XTL Biopharmaceuticals Ltd.
XTLB
$1.27
$0.043.25%
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 33.79% | -7.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 32.45% | -7.36% | |||
| Operating Income | -32.45% | 7.36% | |||
| Income Before Tax | -32.09% | 40.93% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -32.09% | 40.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -32.09% | 40.93% | |||
| EBIT | -32.45% | 7.36% | |||
| EBITDA | -32.49% | 7.37% | |||
| EPS Basic | -25.00% | 42.86% | |||
| Normalized Basic EPS | -- | -- | |||
| EPS Diluted | 0.00% | 14.29% | |||
| Normalized Diluted EPS | -- | -- | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
